Quarterly Industry Update

As of September 30, 2014 Industry: Wearable Devices




Industry Summary

Cogent Valuation identified publicly traded companies, IPOs, and recent M&A transactions within the Wearable Devices industry, which provides a basis for market and transaction pricing that can be used by your firm in estimating market sentiment and its impact on your firm's value. Since September 30, 2013, the median 52-week share price return of the Wearable Devices industry has increased by 22.9%. In the last quarter, the median price-to-earnings multiple decreased from 21.5x to 20.6x.

| Comparable Public Company Key Statist | ics | | | | | | | | | | |
|---|--------|----------------------------|--------|--------|--------|--------------------------------|--------|--------|----------|--------|--------|
| Median 52-Week Return | 22.9% | Median EV/Revenue Multiple | | | 3.5x | Median Price/Earnings Multiple | | | Multiple | 20.6x | |
| Median 3-Year CAGR Return | 17.6% | Median EV/EBITDA Multiple | | | 11.6x | Median EV/Gross CF Multiple | | | 16.3x | | |
| Comparable Public Company Market Price Returns (As of September 30, 2014) | | | | | | | | | | | |
| | YTD | 3 Month | 1 Year | 2 Year | 3 Year | 5 Year | 2013 | 2012 | 2011 | 2010 | 2009 |
| ZELTIQ Aesthetics, Inc. | 19.7% | 49.0% | 150.9% | 100.3% | N/A | N/A | 308.4% | -59.2% | N/A | N/A | N/A |
| Tornier N.V. | 27.2% | 2.2% | 23.6% | 12.3% | 5.3% | N/A | 11.9% | -6.7% | N/A | N/A | N/A |
| Wright Medical Group Inc. | -1.3% | -3.5% | 16.2% | 17.1% | 19.2% | 11.2% | 46.3% | 27.2% | 6.2% | -18.0% | -7.3% |
| Integra LifeSciences Holdings Corporation | 4.0% | 5.5% | 23.3% | 9.9% | 11.5% | 7.8% | 22.4% | 26.4% | -34.8% | 28.3% | 3.7% |
| CONMED Corporation | -13.3% | -16.6% | 8.5% | 13.7% | 17.0% | 14.0% | 52.1% | 8.9% | -2.9% | 15.9% | -4.8% |
| ResMed Inc. | 4.7% | -2.7% | -6.7% | 10.3% | 19.6% | 16.9% | 13.3% | 63.7% | -26.7% | 32.5% | 39.5% |
| CR Bard Inc. | 6.5% | -0.2% | 23.9% | 16.8% | 17.7% | 12.7% | 37.0% | 14.3% | -6.8% | 17.8% | -7.5% |
| Zimmer Holdings, Inc. | 7.9% | -3.2% | 22.4% | 21.9% | 23.4% | 13.5% | 39.8% | 24.8% | -0.5% | -9.2% | 46.2% |
| Exactech Inc. | -3.7% | -9.3% | 13.6% | 13.3% | 17.6% | 7.8% | 40.2% | 2.9% | -12.5% | 8.7% | 2.8% |
| Orthofix International N.V. | 35.7% | -14.6% | 49.1% | -16.8% | -3.6% | 1.0% | -42.0% | 11.6% | 21.5% | -6.2% | 101.8% |
| Median of Industry Public Companies | 5.6% | -2.9% | 22.9% | 13.5% | 17.6% | 11.9% | 38.4% | 13.0% | -4.9% | 12.3% | 3.2% |

(Multiple year periods are calculated as the average annual return.)



| Median Gross Profit, EBITDA, Net Income and Gross Cash Flow Margins |
|--|
| 80.0% — |
| 70.0% |
| 60.0% |
| 50.0% |
| 40.0% |
| 30.0% |
| 20.0% |
| 10.0% |
| 0.0% |
| Sep 2012 Dec 2013 Hat 2013 hur 2013 Sep 2013 Dec 2013 Hat 2014 hur 2014 Sep 2014 |
| Gross Profit — EBITDA — — Net Income — · · - Gross Cash Flow |

| Median Public Company Multiples of the Wearable Devices Industry | | | | | | | | | |
|--|-----------|------------|-----------|-----------|-----------|------------|-----------|-----------|-----------|
| Date: | 9/30/2012 | 12/31/2012 | 3/31/2013 | 6/30/2013 | 9/30/2013 | 12/31/2013 | 3/31/2014 | 6/30/2014 | 9/30/2014 |
| EV/Revenues Multiple | 2.3x | 2.2x | 2.4x | 2.6x | 3.0x | 3.2x | 3.4x | 3.6x | 3.5x |
| EV/EBITDA Multiple | 9.6x | 9.0x | 9.4x | 9.3x | 10.2x | 13.0x | 12.5x | 12.0x | 11.6x |
| Price/Earnings Multiple | 21.6x | 17.7x | 20.9x | 20.9x | 23.7x | 20.8x | 19.6x | 21.5x | 20.6x |
| EV/Gross Cash Flows Multiple | 17.1x | 14.7x | 15.8x | 17.1x | 17.8x | 15.4x | 14.6x | 16.6x | 16.3x |

This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact Steven Kam at 415-392-0888 for additional information or questions in connection with this research report.

Quarterly Industry Update


As of September 30, 2014 Industry: Wearable Devices



| Industry Initial Public Offerings (dollars in millions, except share prices) | | | | | | | | | | |
|--|------------------------------|-------------|----------------|---------------|---------------------|-------------|--------------|------------|----------------|----------------|
| Offer Date | Company Name | Offer Price | Shares Offered | Amount Raised | <u>Total Assets</u> | <u>Debt</u> | LTM Revenues | LTM EBITDA | LTM Net Income | LTM Cash Flows |
| 10/18/2011 | ZELTIQ Aesthetics, Inc. | \$13.00 | 7.0 | \$91.0 | \$21.2 | \$0.6 | \$61.7 | (\$4.8) | (\$6.2) | (\$4.1) |
| 2/2/2011 | Tornier N.V. | \$19.00 | 8.8 | \$166.3 | \$491.2 | \$138.1 | \$227.4 | \$12.4 | (\$39.5) | \$28.0 |
| 7/13/2001 | Wright Medical Group Inc. | \$12.50 | 7.5 | \$93.8 | \$201.6 | \$116.4 | \$164.1 | \$36.7 | (\$22.0) | \$46.8 |
| 5/4/2006 | Northstar Neuroscience, Inc. | \$15.00 | 7.1 | \$106.5 | \$19.1 | \$6.0 | \$0.0 | (\$15.2) | (\$15.0) | (\$15.0) |
| 2/23/2004 | Acelity L.P. Inc. | \$30.00 | 18.0 | \$540.0 | \$4,453.7 | \$2,288.3 | \$6,889.8 | \$416.9 | \$59.7 | N/A |
| Median of Al | l IPOs | nm | nm | \$106.5 | \$201.6 | \$116.4 | \$164.1 | \$12.4 | (\$15.0) | \$11.9 |

nm: not meaningful

| Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions) | | | | | | | | | |
|---|---------------------------|-------------------------|------------------|----------|--|--|--|--|--|
| Transaction Date | Target | Acquirer | Transaction Size | % Bought | | | | | |
| 1/23/2014 | Solta Medical, Inc. | Valeant Pharmaceuticals | \$279.2 | 100% | | | | | |
| 7/16/2013 | Pioneer Surgical Tech. | RTI Biologics, Inc. | \$130.0 | 100% | | | | | |
| 1/4/2013 | Corin Group plc | Investimenti e Part. | \$57.6 | 100% | | | | | |
| 4/25/2012 | ZOLL Medical Corporation | Asahi Kasei Corporation | \$2,216.2 | 100% | | | | | |
| 11/4/2011 | Kinetic Concepts Inc. | Apax Partners LLP | \$6,291.6 | 100% | | | | | |
| 6/24/2011 | Orthovita Inc. | Stryker Corporation | \$331.1 | 100% | | | | | |
| 6/17/2011 | American Medical Systems | Endo Pharmaceuticals | \$2,825.1 | 100% | | | | | |
| 3/4/2011 | O.R. Solutions, Inc. | Ecolab Inc. | \$260.0 | 100% | | | | | |
| 11/16/2010 | Osteotech, Inc. | Medtronic Sofamor | \$135.2 | 100% | | | | | |
| 7/9/2010 | ev3 Inc. | Covidien Group S.a.r.l. | \$2,709.0 | 100% | | | | | |
| 3/26/2010 | Scient'x Groupe S.A.S. | Alphatec Spine, Inc. | \$136.0 | 100% | | | | | |
| 1/8/2010 | Medical House plc | Consort Medical plc. | \$27.5 | 100% | | | | | |
| 6/17/2009 | VNUS Medical Technologies | Covidien, Ltd. | \$470.4 | 100% | | | | | |
| 2/24/2009 | Advanced Medical Optics | Abbott Laboratories | \$2,769.8 | 100% | | | | | |
| 1/30/2009 | Datascope Corp. | Getinge AB | \$865.4 | 100% | | | | | |
| Median of All Transaction Targets \$331.1 100% | | | | | | | | | |



Disclosures and Limitations: This research report is for informational and discussion purposes only. Information presented herein is not investment advice of any kind to any person and does not constitute a recommendation as to the purchase or sale of any interests or as to any other course of action. General, financial, and statistical information concerning the details of this report and related industry are from sources Cogent Valuation believes to be reliable. Cogent Valuation has accurately reflected such information in this research report; however, Cogent Valuation makes no representation as to the sources' accuracy or completeness and has accepted this information without further verification. Neither all nor any part of the content of this report may be conveyed to the public through advertising, public relations, news, sales, mail, direct transmittal, or other media without the prior written consent of Cogent Valuation. Cogent Valuation's research is as of the date reported herein. Cogent Valuation has no affiliation with any of the companies comprising the industry used as a basis for research in this report, nor does Cogent Valuation hold any investments in the companies listed herein. The content of this report may be used, in part, as a basis for any work that Cogent Valuation performs for you in the future at the sole discretion of Cogent Valuation. THIS REPORT IS NOT TO BE USED OR CONSIDERED UNDER ANY CIRCUMSTANCE BY ANYONE AS INVESTMENT ADVICE. This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact Steven Kam at 415-392-0888 for additional information or questions in connection with this research report. Copyright © 2014 Cogent Valuation. All Rights Reserved.